
Sangamo Therapeutics SGMO
Sangamo Therapeutics Interest Expense | SGMO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Sangamo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.56 M | 4.35 M | - | - | - | - | - | - | - | 887 K | 431 K | 364 K | 82 K | - | - | - | 268 K | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.35 M | -3.56 M | 402 K |
Quarterly Interest Expense Sangamo Therapeutics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 651 K | 107 K | -2.49 M | -1.16 M | -221 K | 614 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 651 K | -2.49 M | -416 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Intellia Therapeutics
NTLA
|
28.3 M | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
1.11 M | $ 1.8 | -10.56 % | $ 106 M | ||
|
Pfizer
PFE
|
2.67 B | $ 27.4 | -0.62 % | $ 156 B | ||
|
Amarin Corporation plc
AMRN
|
7 K | $ 10.56 | -6.26 % | $ 4.38 B | ||
|
ImmuCell Corporation
ICCC
|
476 K | $ 11.08 | -0.81 % | $ 100 M | ||
|
Editas Medicine
EDIT
|
-2.19 M | $ 1.63 | -4.68 % | $ 145 M | ||
|
Agios Pharmaceuticals
AGIO
|
1.96 M | $ 27.54 | -4.24 % | $ 1.6 B | ||
|
Royalty Pharma plc
RPRX
|
-14.3 M | $ 68.45 | 1.08 % | $ 29.4 B | ||
|
Equillium
EQ
|
-76 K | $ 1.06 | -5.36 % | $ 60.7 M | ||
|
Black Diamond Therapeutics
BDTX
|
5.78 M | $ 1.32 | -5.04 % | $ 75.1 M | ||
|
Abeona Therapeutics
ABEO
|
3.74 M | $ 2.42 | -1.17 % | $ 128 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
2.37 M | $ 17.1 | -2.79 % | $ 2.88 B | ||
|
Atossa Therapeutics
ATOS
|
-6 K | $ 1.6 | -8.86 % | $ 13.8 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
1.26 M | $ 112.31 | -3.84 % | $ 7.3 B | ||
|
ADC Therapeutics SA
ADCT
|
22.7 M | $ 1.29 | -2.28 % | $ 164 M | ||
|
Harmony Biosciences Holdings
HRMY
|
-680 K | $ 32.58 | -1.21 % | $ 1.87 B | ||
|
Ardelyx
ARDX
|
4.95 M | $ 2.99 | -2.25 % | $ 721 M | ||
|
Akebia Therapeutics
AKBA
|
58 K | $ 0.39 | -8.41 % | $ 100 M | ||
|
Alector
ALEC
|
13.2 M | $ 2.34 | 1.52 % | $ 241 M | ||
|
ALX Oncology Holdings
ALXO
|
1.6 M | $ 1.06 | 3.43 % | $ 56.9 M | ||
|
Amneal Pharmaceuticals
AMRX
|
16.5 M | $ 21.12 | -1.26 % | $ 6.62 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
459 K | $ 4.03 | -1.11 % | $ 772 M | ||
|
Agenus
AGEN
|
72.4 M | $ 5.97 | -2.85 % | $ 178 M | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 9.63 | -8.02 % | $ 2.88 B | ||
|
Artelo Biosciences
ARTL
|
194 K | $ 1.35 | -6.9 % | $ 255 K | ||
|
Immatics N.V.
IMTX
|
946 K | $ 5.76 | -3.19 % | $ 705 M | ||
|
Aptevo Therapeutics
APVO
|
345 K | $ 0.4 | -2.61 % | $ 126 K | ||
|
Aligos Therapeutics
ALGS
|
2.2 M | $ 1.22 | -2.4 % | $ 12.1 M | ||
|
Aclaris Therapeutics
ACRS
|
8.51 M | $ 3.44 | -1.86 % | $ 422 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
11.8 M | $ 27.46 | -2.1 % | $ 4.17 B | ||
|
Cellectar Biosciences
CLRB
|
-426 | $ 0.83 | -8.27 % | $ 2.16 M | ||
|
SIGA Technologies
SIGA
|
3.02 M | $ 2.4 | -9.06 % | $ 172 M | ||
|
Capricor Therapeutics
CAPR
|
399 K | $ 7.56 | 0.4 % | $ 351 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
23 K | $ 28.3 | 0.68 % | $ 1.32 B | ||
|
Syndax Pharmaceuticals
SNDX
|
-1.28 M | $ 8.71 | -4.16 % | $ 755 M | ||
|
Aquestive Therapeutics
AQST
|
6.34 M | $ 3.47 | -6.48 % | $ 371 M | ||
|
Pliant Therapeutics
PLRX
|
1.27 M | $ 0.59 | -4.42 % | $ 36.2 M | ||
|
Jaguar Health
JAGX
|
67 K | $ 0.24 | -27.06 % | $ 560 K | ||
|
Arvinas
ARVN
|
-400 K | $ 6.41 | -4.9 % | $ 454 M | ||
|
Cerus Corporation
CERS
|
3.02 M | $ 1.86 | -2.37 % | $ 355 M |